2023版国际抗癫痫联盟指南解读:新生儿惊厥发作的治疗  

Interpretation of 2023 International League Against Epilepsy guidelines:treatment of seizures in the neonate

作　　者：赵仕国 杨子浩[1] 陈振杰[1] 夏姗姗[1] 何玮梅 楼晓芳[1] 周红琴[1] 邵琪琪 张晨美[1] Zhao Shiguo;Yang Zihao;Chen Zhenjie;Xia Shanshan;He Weimei;Lou Xiaofang;Zhou Hongqin;Shao Qiqi;Zhang Chenmei(Children′s Hospital Affiliated to Zhejiang University School of Medicine,National Clinical Research Center of Child Health and Disease,Hangzhou 310052,China)

机构地区：[1]浙江大学医学院附属儿童医院,国家儿童健康与疾病临床医学研究中心,杭州310052

出　　处：《中华神经科杂志》2024年第6期682-688,共7页Chinese Journal of Neurology

基　　金：国家重点研发计划(2021YFC2701800,2021YFC2701801)。

摘　　要：2023年国际抗癫痫联盟(ILAE)新生儿工作组根据ILAE指南制订标准提出了关于新生儿惊厥抗癫痫发作药物临床管理的6个必要问题,并给出循证建议,指南基本框架为系统评价+专家共识。该文主要对2023年国际抗癫痫联盟指南的临床推荐意见及其与ILAE 2011版指南的异同点进行分析与解读,以期为我国参与新生儿惊厥管理的同行提供参考。According to the International League Against Epilepsy(ILAE)standards,the Newborn Working Group of the ILAE put forward 6 necessary questions about the management of neonatal anti-seizure medication and gave evidence-based recommendations in 2023.The basic framework is systematic review+expert consensus.The clinical recommendations of ILAE guidelines 2023 and the similarities and differences between ILAE guidelines 2023 and ILAE guidelines 2011 were analyzed and interpreted in this paper,in order to provide reference for colleagues involved in neonatal convulsion management in China.

关 键 词：抗惊厥药 婴儿 新生 亚低温治疗 指南 

分 类 号：R742.1[医药卫生—神经病学与精神病学]